Obeticholic acid (OCA), a potent farnesoid X receptor agonist, was studied as monotherapy
in an international, randomized, double‐blind, placebo‐controlled phase 2 study in patients …

Background & aims Obeticholic acid (OCA) is the second-line treatment approved for
patients with primary biliary cholangitis (PBC) and an inadequate response or intolerance to …

Background The aim of this study was to evaluate the long-term efficacy and safety of
obeticholic acid for patients with primary biliary cholangitis using 3-year interim data from the …

Obeticholic acid (Ocaliva TM) is a farnesoid-X receptor (FXR) agonist that is being
developed by Intercept Pharmaceuticals for the treatment of various liver diseases, and has …

Background Primary biliary cholangitis (formerly called primary biliary cirrhosis) can
progress to cirrhosis and death despite ursodiol therapy. Alkaline phosphatase and bilirubin …

Background & Aims Primary sclerosing cholangitis (PSC) is a rare, cholestatic liver disease
with no currently approved therapies. Obeticholic acid (OCA) is a potent farnesoid X receptor …

Background & Aims We evaluated the efficacy and safety of obeticholic acid (OCA, α-
ethylchenodeoxycholic acid) in a randomized controlled trial of patients with primary biliary …

Primary biliary cholangitis (PBC), formerly called primary biliary cirrhosis, is a chronic
cholestatic liver disease that progresses slowly to end-stage liver disease. The first Food …

Primary biliary cholangitis (PBC) is a chronic, progressive autoimmune liver disease that
mainly affects middle‐aged women. Obeticholic acid (OCA), which was recently approved …

Primary biliary cholangitis (formerly known as primary biliary cirrhosis, PBC) is an
autoimmune liver disease in which a cycle of immune mediated biliary epithelial cell injury …